ImevaX
Latest round
- Series A
Last raised
- Feb 2015
Total raised
- $8.5M
Investors
- 5
About ImevaX
Founded in 2014 and headquartered in Munich, Germany, ImevaX specializes in the development of therapies for autoimmune diseases. The CEO, Volker Wedershoven, has a history in the biotech sector, although there are no details on other companies he has founded.ImevaX offers a range of therapeutic solutions designed to address autoimmune diseases, utilizing cutting-edge immunological and genetic research. Their products aim to provide targeted treatment options, enhancing patient outcomes in managing these complex conditions. The company aims to expand its presence in European markets and explore opportunities in North America by 2025.
Who invested in ImevaX
5 investors across 1 round
See all investors in ImevaX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 27, 2015
Amount
$8.5M
Investors
Questions about ImevaX
Who invested in ImevaX?
ImevaX has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImevaX raised?
ImevaX has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ImevaX last raise money?
ImevaX's most recent round on record is a Series A, in Feb 2015.
What does ImevaX do?
Founded in 2014 and headquartered in Munich, Germany, ImevaX specializes in the development of therapies for autoimmune diseases.
Where is ImevaX headquartered?
ImevaX is headquartered in Munich, Germany.
Which VCs invest in companies like ImevaX?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at ImevaX's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like ImevaX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.